The Impressive TimesIndia has introduced a new immunotherapy injection designed for patients suffering from non-small cell lung cancer (NSCLC), one of the most commonly diagnosed forms of lung cancer in the country. The latest treatment is being seen as a major advancement because it significantly reduces the time required for administering cancer therapy.
Until now, patients receiving this immunotherapy had to undergo lengthy intravenous (IV) infusions inside hospitals. With the launch of the new subcutaneous (SC) injection, the same treatment can now be delivered directly under the skin within approximately seven minutes.
Medical experts believe this innovation may improve patient comfort, reduce waiting time in hospitals, and increase treatment capacity in cancer care centers across India.
The treatment is mainly intended for patients diagnosed with non-small cell lung cancer. According to health estimates, thousands of new lung cancer cases are detected in India every year, and NSCLC accounts for a large percentage of them.
However, doctors say the injection is not suitable for every patient. The medicine specifically targets cancer cells carrying high levels of the PD-L1 protein. Patients whose tumors show elevated PD-L1 expression are considered more likely to benefit from this immunotherapy.
Specialists estimate that nearly half of NSCLC patients may qualify for this targeted treatment after proper medical testing.
The human immune system contains T-cells, which normally identify and destroy harmful or abnormal cells in the body. Cancer cells, however, often escape detection by producing a protein called PD-L1. This protein acts like a shield, preventing the immune system from attacking the tumor.
The newly introduced drug works by blocking the PD-L1 protein. Once the protein is blocked, T-cells can again recognize cancer cells and help the body fight the disease more effectively.
Doctors describe this process as a major advancement in targeted cancer therapy because it uses the body’s own immune defense system to attack tumors.
Previously, patients had to spend several hours in hospitals while receiving the medicine through IV infusion. The new SC injection method allows doctors to administer the treatment in the thigh area within minutes.
Healthcare professionals say this could greatly reduce pressure on hospitals and chemotherapy units. Instead of treating only one patient during long infusion sessions, hospitals may now handle multiple patients in the same time frame.
Global patient preference studies have also shown that most patients favor quick injections over lengthy IV procedures because they are more convenient and less stressful.
Despite the medical breakthrough, the treatment remains expensive. Reports suggest that one dose of the injection costs around Rs 3.7 lakh in India. In many cases, patients may require multiple doses depending on their treatment plan.
To support patients financially, the pharmaceutical company has introduced a patient assistance initiative aimed at reducing the overall treatment burden. The therapy has also reportedly been included under the Central Government Health Scheme (CGHS), offering additional relief to eligible beneficiaries.
The newer SC injection uses a different dosage strength compared to the earlier IV version, which also creates a price variation between the two treatment methods.
No Comments: